SCHEMBL20546308

SCHEMBL20546308

COc1ccc(C)c(-c2cccc(C(N)CC(=O)O)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CTSA P10619 17/20 0.53
FFAR1 O14842 2/20 0.48
PPARD Q03181 1/20 0.48
KMT2A Q03164 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20546306 1.00 CTSA (0.53) CTSAFFAR1PPARDKMT2ASMN1; SMN2
SCHEMBL20546551 0.92 FFAR1 (0.53) CTSAFFAR1PPARDKMT2ASMN1; SMN2
SCHEMBL20546554 0.92 FFAR1 (0.53) CTSAFFAR1PPARDKMT2ASMN1; SMN2
SCHEMBL20546206 0.88 CTSA (0.63) CTSA
SCHEMBL20546204 0.88 CTSA (0.63) CTSA
SCHEMBL30541303 0.87 PPARG (0.44) CTSAFFAR1PPARD
SCHEMBL20546250 0.86 CTSA (0.63) CTSA
SCHEMBL20546249 0.86 CTSA (0.63) CTSA
SCHEMBL20546570 0.85 CTSA (0.47) CTSAKMT2ASMN1; SMN2
SCHEMBL20546571 0.85 CTSA (0.47) CTSAKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3615514-B1 PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS INC (US) 2023-11-22 EP disclosed
US-10875875-B2 Propionic acid derivatives and methods of use thereof AVIARA PHARMACEUTICALS, INC. (US) 2020-12-29 US disclosed
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof AVIARA PHARMACEUTICALS, INC. (US) 2018-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180312523-A1 Propionic Acid Derivatives and Methods of Use Thereof ITGB3, ITGA1, ITGB5 CTSA 2240/4885FFAR1 37/4885PPARD 423/4885
US-10875875-B2 Propionic acid derivatives and methods of use thereof ITGB3, ITGA1, ITGB5 CTSA 2240/4885FFAR1 37/4885PPARD 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.